Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2021-06-22 Regulatory Filings
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release from Mauna Kea Technologies announcing a new peer-reviewed publication in the journal 'Nature Scientific Reports' regarding their Cellvizio platform's accuracy for food allergy diagnosis. This is not a full financial report (like 10-K or IR), nor is it a transcript, management discussion, or a formal regulatory filing like a proxy statement or dividend notice. It is an announcement about scientific/clinical progress, which often falls under general Investor Relations (IR) or Regulatory Filings (RNS). Since the content is focused on clinical validation and market potential stemming from a scientific publication, it aligns best with general Investor Relations communication, but given the specific options, it is a general announcement of company activity/news. It is not a Report Publication Announcement (RPA) because it is announcing the *content* of the publication, not just the *release* of a financial report. It is most closely related to Investor Relations/Company Information. Given the available codes, 'IR' (Interim/Quarterly Report) is incorrect. 'RNS' (Regulatory Filings/Miscellaneous) is a strong candidate for general news releases that don't fit elsewhere. However, since it is a press release detailing clinical/scientific progress, it is often categorized broadly under Investor Relations material. Since there is no specific 'Press Release' or 'Scientific Update' code, and it is not a formal financial report, 'RNS' serves as the best general regulatory/announcement fallback.
2021-06-22 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 98% confidence The document is titled "Mise à disposition du Document d'Enregistrement Universel 2020" (Making available of the 2020 Universal Registration Document). It explicitly states that the company has made available and filed its Universal Registration Document (Document d'Enregistrement Universel - DEU) for the fiscal year ended December 31, 2020, with the French financial market authority (AMF). The DEU contains the annual financial report, management report, and corporate governance report. Crucially, the document itself is an announcement stating that the main report is available elsewhere ("Le Document d'Enregistrement Universel est disponible sur le site..."). Given the short length (3900 chars) and the nature of announcing the publication of a major report, this fits the definition of a Report Publication Announcement (RPA). While the DEU contains elements of a 10-K (Annual Report), this specific text is the announcement of its availability.
2021-06-21 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated June 14, 2021, announcing the unveiling of Mauna Kea Technologies' next-generation Cellvizio® platform, highlighting its FDA 510(k) clearance and CE marking, and providing details about new features and availability. This type of announcement, detailing a significant product launch or development, is typically classified as a general corporate announcement or news release. Since there is no specific category for 'Product Launch Announcement' and it is not a formal financial filing (like 10-K, IR, ER), the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous regulatory or significant corporate news releases that don't fit elsewhere. The length (5173 chars) is substantial enough that it is the primary document, not just an announcement of an attachment (ruling out RPA).
2021-06-14 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated June 14, 2021, announcing the launch of Mauna Kea Technologies' next-generation Cellvizio® platform. It details product features, regulatory clearances (FDA 510(k), CE marking), and includes forward-looking statements and contact information. This type of announcement, focusing on a significant product launch or corporate development that is not a standard periodic financial report (like 10-K or IR), typically falls under a general regulatory announcement or news release category. Since there is no specific category for 'Product Launch Announcement' and it is not a formal financial filing, the most appropriate general category is 'Regulatory Filings' (RNS), which serves as a fallback for miscellaneous regulatory/corporate news releases that don't fit the other specific codes (like ER, CAP, or LTR). The document length (4750 chars) is substantial enough that it is the primary content, not just a brief announcement of an attached report.
2021-06-14 English
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release from Mauna Kea Technologies announcing that they will have 7 presentations highlighting their Cellvizio platform at the Digestive Disease Week (DDW) 2021 Virtual conference. It details the titles, authors, and presentation times for these scientific abstracts. This type of announcement, which publicizes participation in an industry event or conference where research findings are presented, is best classified as a general announcement or press release related to investor/company activity, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific report (AR, IR). Since it is an announcement about scientific data being presented at a conference, and it doesn't fit the specific categories like ER, IR, or AR, it falls under the general category for regulatory/corporate announcements that don't fit elsewhere, which is RNS (Regulatory Filings/Miscellaneous Announcements). It is not an Investor Presentation (IP) as it is announcing *other people's* presentations, nor is it a Report Publication Announcement (RPA) as it is not announcing the publication of a formal company report (like an Annual Report or Quarterly Report).
2021-05-20 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Mauna Kea Technologies announcing their participation and the presentation of 7 studies related to their Cellvizio product at the Digestive Disease Week® (DDW) 2021 virtual conference. It details the topics, presentation times, and authors, and provides general information about the conference and the company. This type of announcement, which publicizes participation in an industry event or conference where research findings are presented, does not fit neatly into the specific financial filing categories like 10-K, ER, or IR. It is a general corporate communication about scientific/clinical updates. Since it is not a formal regulatory filing (like a 10-K or MRQ) nor a specific announcement like a dividend or management change, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous corporate announcements that are not covered by other specific codes.
2021-05-20 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.